Anika Therapeutics, Inc. (ANIK) — Financial statements
Income statement, balance sheet, and cash flow for Anika Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 113↓5.9% | 120↓0.7% | 121↑6.1% | 114↓23.0% | 148 | |
| Cost of Revenue | 49↑11.6% | 44↑14.8% | 38↓5.8% | 41↓37.4% | 65 | |
| Gross Profit | 64↓16.0% | 76↓7.9% | 83↑12.7% | 73↓11.7% | 83 | |
| Operating Expenses | ||||||
| R&D Expenses | 26↑0.9% | 26↑17.4% | 22↑18.8% | 18↓33.0% | 27 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 49↓11.6% | 56↓7.3% | 60↑17.0% | 51↓30.9% | 74 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -21 | |
| Operating Expenses | 75↓7.7% | 81↓0.7% | 82↑17.5% | 70↓13.4% | 80 | |
| Total Costs & Expenses | 124↓0.9% | 125↑4.2% | 120↑8.9% | 110↓24.1% | 145 | |
| Operating Results | ||||||
| Operating Income | -11↓116.6% | -5↓704.4% | 0.84↓77.0% | 4↑40.3% | 3 | |
| Depreciation & Amortization | 6↓29.5% | 8↓42.9% | 14↓1.9% | 14↑1.2% | 14 | |
| EBITDA | -5↓276.2% | 3↓79.9% | 15↓17.1% | 18↑536.2% | -4 | |
| EBIT | -11↓116.6% | -5↓704.4% | 0.84↓77.0% | 4↑119.9% | -18 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00 | 0.00↓100.0% | 2↑253.5% | 0.65 | 0.00 | |
| Interest Income | 0.00 | — | 2↑253.5% | 0.65 | — | |
| Interest Expense | 0.00 | — | 0.00 | 0.00 | — | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 21 | |
| Other Income / Expenses | 2↓25.4% | 2↑1.1% | 2↑253.5% | 0.65↑447.9% | -0.19 | |
| Income Before Tax | -9↓236.7% | -3↓187.6% | 3↓27.0% | 4↑78.2% | 2 | |
| Income Tax Expense | 0.67↓88.9% | 6↓8.1% | 7↑210.5% | 2↑224.4% | -2 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -10↓13.0% | -9↓156.7% | -3↓256.3% | 2↓46.8% | 4 | |
| Net Income from Discontinued Operations | -0.90↑98.1% | -48↑40.0% | -79↓364.4% | -17 | 0.00 | |
| Net Income | -11↑80.7% | -56↑31.8% | -83↓456.3% | -15↓459.4% | 4 | |
| Bottom-Line Net Income | -11↑80.7% | -56↑31.8% | -83↓456.3% | -15↓459.4% | 4 | |
| EPS (Basic) | -0.76↑80.2% | -3.83↑32.1% | -5.64↓452.9% | -1.02↓451.7% | 0.29 | |
| EPS (Diluted) | -0.76↑80.2% | -3.83↑32.1% | -5.64↓452.9% | -1.02↓464.3% | 0.28 | |
| Weighted Average Shares | 14↓2.6% | 15↑0.4% | 15↑0.7% | 15↑1.1% | 14 | |
| Weighted Average Diluted Shares | 14↓2.6% | 15↑0.4% | 15↑0.7% | 15↓0.5% | 15 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.